71

L B E Shields1, H Hust, S D Cooley

  • 1Kenneth G. Pugh, MD, MSc, Norton Neuroscience Institute Memory Center, Norton Healthcare, Norton Medical Plaza III- Brownsboro, Suite 300, 4915 Norton Healthcare Blvd. Louisville, KY 40241 U.S.A., (502) 394-6460 (Office); (502) 394-6465 (FAX),

概括

在早期患者体验中,阿尔茨海默病的Lecanemab (Leqembi®) 治疗显示了24%的粉样蛋白相关成像异常 (ARIA) 和37%的输液反应. 这些发现突出了改善lecanemab输注过程的领域.